Photo of Olga Pozdnyakova,  MD

Olga Pozdnyakova, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 525-8905

Olga Pozdnyakova, MD

Brigham And Women's Hospital


  • Associate Professor, Pathology, Harvard Medical School
  • Associate Pathologist, Pathology, Brigham And Women's Hospital


Research Abstract

I am currently a Diagnostic Hematopathologist at Brigham and Women's Hospital and Dana Farber Cancer Institute (DFCI) and an Associate Professor of Pathology at Harvard Medical School. I am the Associate Medical Director of the Clinical Hematology Laboratory at BWH and the Medical Director of the Physicians Diagnostic Laboratories at Brigham and Women’s Harbor Medical Associates (HMA) and DFCI Cancer Center and the Community Cancer Care in Weymouth.

As a member of the Hematopathology Division at BWH and a Hematopathologist, I provide comprehensive diagnostic evaluation of patients specimens, including conventional histology, as well as specialized immunological, molecular and flow cytometric tests, that result in an integrated diagnostic reports. My particular clinical expertise lies in myeloproliferative neoplasms and I am frequently consulted by my colleagues and pathologists at outside institutions. In addition, I participate in direct day-to-day instruction and education in all aspects of Hematopathology and Clinical Hematology to the fellows and residents. I also present weekly interactive clinical case conferences within the Division of Hematopathology and DFCI clinical pathologic correlation conferences. I am the course director of a bi-weekly Hematology Laboratory and Coagulation Journal Club with pathology trainees, faculty and laboratory staff. I also serve as a tutor in the Human Systems Course at Harvard Medical School. I have organized and lectured in courses at several national and international pathology conferences, including the College of American Pathologists and American Society of Clinical Pathologists. I have co-authored a textbook Hematopathology: A Volume in the High Yield Pathology Series and have authored chapters in numerous Hematology and Pathology textbooks.

My research efforts are focused on the development and application of novel approaches to diagnosing and prognostication of hematologic diseases, with specific interest in myeloid neoplasms. Using a novel gene expression platform, I analyze the contribution of the inflammatory microenvironment to the pathogenesis of myeloproliferative neoplasms. I serve as a central pathologist reviewer in several clinical trials of novel therapeutic agents for myeloproliferative neoplasm. I am also studying novel hematologic parameters on Sysmex hematology analyzers that could be used as diagnostic screening tests for cytopenic patients, potentially avoiding unnecessary and costly tests in the workup of this common clinical scenario.


Powered by Harvard Catalyst
  • Weinberg OK, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP. Association of mutations with morphological dysplasia inacute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica 2018; 103:626-633. PubMed
  • Keegan A, Charest K, Schmidt R, Briggs D, Deangelo DJ, Li B, Morgan EA, Pozdnyakova O. Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. J Clin Pathol 2018. PubMed
  • Craig JW, Mina MJ, Crombie JL, LaCasce AS, Weinstock DM, Pinkus GS, Pozdnyakova O. Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. PLoS ONE 2018; 13:e0199708. PubMed
  • Mason EF, Kuo FC, Hasserjian RP, Seegmiller AC, Pozdnyakova O. A Distinct Immunophenotype Identifies a Subset of NPM1-mutated AML With TET2 or IDH1/2 Mutations and Improved Outcome. Am J Hematol 2017. PubMed
  • Wong WJ, Hasserjian RP, Pinkus GS, Breyfogle LJ, Mullaly A, Pozdnyakova O. JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histologic features in Philadelphia chromosome-negative myeloproliferative neoplasms. Haematologica 2017. PubMed
  • Ho VT, Kim HT, Bavli N, Mihm M, Pozdnyakova O, Piesche M, Daley H, Reynolds C, Souders NC, Cutler C, Koreth J, Alyea EP, Antin JH, Ritz J, Dranoff G, Soiffer RJ. Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv 2018; 1:2269-2279. PubMed
  • Mason EF, Pozdnyakova O, Li B, Dudley G, Dorfman DM. Flow Cytometric Patterns of CD200 and CD1d Expression Distinguish CD10-Negative, CD5-Negative Mature B-Cell Lymphoproliferative Disorders. Am J Clin Pathol 2017; 148:33-41. PubMed
  • Shanmugam V, Craig JW, Hornick JL, Morgan EA, Pinkus GS, Pozdnyakova O. Cyclin D1 is Expressed in Neoplastic Cells of Langerhans Cell Histiocytosis but Not Reactive Langerhans Cell Proliferations. Am J Surg Pathol 2017. PubMed
  • Weinberg OK, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP. NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO Classification. Am J Hematol 2017. PubMed
  • Weinberg OK, Hasserjian RP, Li B, Pozdnyakova O. Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category. J Clin Pathol 2016. PubMed
  • Dorfman DM, LaPlante CD, Pozdnyakova O, Li B. FLOCK cluster analysis of mast cell event clustering by high-sensitivity flow cytometry predicts systemic mastocytosis. Am J Clin Pathol 2015; 144:764-70. PubMed
  • Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, Thiele J, Rodig S, Pozdnyakova O. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med 2016; 13:294. PubMed
  • Pozdnyakova O, Laplante CD, Li B, Rosner B, Dorfman DM. High-sensitivity flow cytometric analysis of mast cell clustering in systemic mastocytosis: a quantitative and statistical analysis. Leuk Lymphoma 2015; 56:1735-41. PubMed
  • Pozdnyakova O, Hasserjian RP, Verstovsek S, Orazi A. Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk 2015. PubMed
  • Mandelker DL, Dorfman DM, Li B, Pozdnyakova O. Antigen expression patterns of MYC-rearranged versus non-MYC-rearranged B-cell lymphomas by flow cytometry. Leuk Lymphoma 2017; 55:2592-6. PubMed
  • Pozdnyakova O, Wu K, Patki A, Rodig SJ, Thiele J, Hasserjian RP. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. Mod Pathol 2014. PubMed